23 Dec 2025 β European equities traded mixed with small moves on major indexes as holiday-thinned liquidity weighed. Solid performance on Wall Street the previous day failed to produce a full follow-through in Asia or Europe, leaving major bourses largely rangebound. #EuropeanStocks #FiatNews
23 Dec 2025 β Japanβs market moves were limited and responded mainly to verbal interventions by authorities rather than sustained trading flows. Local equities showed only short-lived reactions to commentary, while broader Asian markets did not mirror Wall Streetβs prior strength. #Japan #FiatNews
23 Dec 2025 β Novo Nordisk shares rose after regulatory approval of a drug, making the company one of the day's stronger single-stock performers. The advance occurred as investors traded cautiously ahead of the holidays amid generally modest market activity across Europe. #NovoNordisk #FiatNews
On Dec. 23, 2025 the U.S. third-quarter GDP figure β the last major macro release postponed by the recent government shutdown β is scheduled for publication, with attention focused on whether annualized growth approached 4%. The question of a near-4% pace has been a central talking point ahead of todayβs release.
This data point was the final delayed number from the period of federal agency closures and will provide a complete picture of economic activity in Q3. Early estimates and commentary have emphasized the annualized rate as the key headline.
The quarterβs GDP print is a primary gauge of overall economic momentum and will be closely examined by analysts and investors assessing recent growth dynamics. #USGDP #GDP #Q3 #macroeconomics #FiatNews
Novo Nordisk has won U.S. approval to market a tablet version of its obesity drug Wegovy, a move Bloomberg says is key to defending the companyβs market share against rival Eli Lilly. The authorization, reported on Dec. 23, 2025, allows Novo Nordisk to offer an oral formulation of the medicine in the U.S. market.
The approval represents a strategic step to broaden patient access and compete more directly with emerging alternatives from Eli Lilly. Wegovy is already established as a treatment for obesity; the tablet launch could affect prescribing patterns and market dynamics in the sector.
Bloomberg is the source of the report; no additional sales forecasts or regulatory conditions were cited in the item. #NovoNordisk #Wegovy #EliLilly #obesity #FiatNews
Czech Prime Minister Andrej BabiΕ‘ announced which trust fund he will transfer the Agrofert holding into, signaling an official move of the conglomerate into a designated fiduciary structure. Further details on the chosen fund were disclosed by the prime minister. #Agrofert #CzechRepublic #FiatNews
